Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cell Procurement

Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation

Bone Marrow Transplantation volume 47, pages 488–493 (2012)Cite this article

Abstract

Fludarabine is an effective treatment for follicular lymphoma (FL), but exposure to it negatively impacts stem cell mobilization and may increase the risk of subsequent myelodysplastic syndrome and acute myelogenous leukemia (t-MDS/AML). We hypothesized that the risk that fludarabine imparts to stem cell mobilization and t-MDS/AML would be affected by dose or timing. All patients with FL treated at Cleveland Clinic from 1991 to 2007 with autologous hematopoietic cell transplantation were evaluated. Recursive partitioning analysis was used to explore associations of fludarabine and mitoxantrone dose and timing with poor stem cell harvest and t-MDS/AML. We identified 171 patients, of whom 52 previously received fludarabine. Patients exposed to fludarabine prior to auto-HCT were more likely to require >5 days of leukapheresis (P<0.001) and second stem cell mobilization (P<0.001), especially at a cumulative dose >150 mg/m2. Univariable risk factors for t-MDS/AML included the number of chemotherapy regimens before auto-HCT, the need for >5 days of leukapheresis to collect CD34+ cells and fludarabine exposure in a dose-dependent manner, particularly when >500 mg/m2. A cumulative dose of fludarabine >150 mg/m2 increases the risk for poor stem cell harvests and any exposure increases the risk of t-MDS/AML, with the greatest risk being at doses >500 mg/m2.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S . Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003; 21: 897–906.

    Article  PubMed  Google Scholar 

  2. Micallef IN, Lillington DM, Apostolidis J, Amess JA, Neat M, Matthews J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18: 947–955.

    Article  CAS  PubMed  Google Scholar 

  3. Misgeld E, Germing U, Aul C, Gattermann N . Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma. Leuk Res 2001; 25: 95–98.

    Article  CAS  PubMed  Google Scholar 

  4. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Appelbaum FR, Hines JD et al. Therapy-related myeloid leukemia's are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 2002; 20: 3878–3884.

    Article  PubMed  Google Scholar 

  5. Tam CS, Seymour JF, Prince HM, Kenealy M, Wolf M, Januszewicz EH et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 2006; 91: 1546–1550.

    CAS  PubMed  Google Scholar 

  6. Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004; 22: 2654–2661.

    Article  CAS  PubMed  Google Scholar 

  7. McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14: 1262–1268.

    Article  CAS  PubMed  Google Scholar 

  8. Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009; 27: 1202–1208.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Visani G, Lemoli RM, Tosi P, Martinelli G, Testoni N, Ricci P et al. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukemia patients. Br J Haematol 1999; 105: 775–779.

    Article  CAS  PubMed  Google Scholar 

  10. Tournilhac O, Cazin B, Lepretre S, Divine M, Maloum K, Delmer A et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103: 363–365.

    Article  PubMed  Google Scholar 

  11. Bolwell B, Kalaycio M, Sobecks R, Andresen S, Mcbee M, Kuczkowski L et al. Autologous hematopoietic cell transplantation for non-Hodgkin's lymphoma: 100 month follow-up. Bone Marrow Transplant 2002; 29: 673–679.

    Article  CAS  PubMed  Google Scholar 

  12. Maloney DG . Treatment of follicular non-Hodgkin's lymphoma. Curr Hematol Rep 2005; 4: 39–45.

    Article  CAS  PubMed  Google Scholar 

  13. Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Andresen S, Kuczkowski E et al. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 2006; 24: 3604–3610.

    Article  PubMed  Google Scholar 

  14. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392.

    CAS  PubMed  Google Scholar 

  15. Copelan EA, Penza SL, Pohlman B, Avalos BR, Goormastic M, Andresen SW et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2000; 25: 1243–1248.

    Article  CAS  PubMed  Google Scholar 

  16. Bolwell BJ, Pohlman B, Andresen S, Kalaycio M, Goormastic M, Wise K et al. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplant 1998; 21: 369–373.

    Article  CAS  PubMed  Google Scholar 

  17. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute leukemia. Ann Intern Med 1985; 103: 620–629.

    Article  CAS  PubMed  Google Scholar 

  18. Saso R, Kulkarni S, Mitchell P, Treleaven J, Swansbury GJ, Mehta J et al. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer 2000; 83: 91–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Morgan SJ, Seymour JF, Grigg A, Matthews JP, Prince HM, Wolf MM et al. Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine. Leukemia 2004; 18: 1034–1038.

    Article  CAS  PubMed  Google Scholar 

  20. Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Gobbi PG et al. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008; 93: 398–404.

    Article  PubMed  Google Scholar 

  21. Laurenti L, Tarnani M, Chiusolo P, La Torre G, Garzia M, Zollino M et al. Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: the role of pre-transplant therapy. Clin Transplant 2008; 22: 191–199.

    Article  PubMed  Google Scholar 

  22. Bowcock SJ, Rassam SM, Lim Z, Ward SM, Ryali MM, Mufti GJ . High incidence of therapy-related myelodysplasia and acute leukemia in general hematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders. Br J Haematol 2006; 134: 242–243.

    Article  PubMed  Google Scholar 

  23. Yamauchi T, Nowak BJ, Keating MJ, Plunkett W . DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001; 7: 3580–3589.

    CAS  PubMed  Google Scholar 

  24. Eissner G, Multhoff G, Gerbitz A, Kirchner S, Bauer S, Haffner S et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood 2002; 100: 334–340.

    Article  CAS  PubMed  Google Scholar 

  25. Berger MG, Berger J, Richard C, Jeanpierre S, Nicolini FE, Tournilhac O et al. Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization. Leukemia 2008; 22: 2131–2134.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USA

    J Waterman, B Bolwell, E Copelan, B Pohlman, J Sweetenham, R Dean, R Sobecks, S Andresen & M Kalaycio

  2. Department of Quantitative Health Sciences, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USA

    L Rybicki

Authors
  1. J Waterman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Rybicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Bolwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Copelan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Pohlman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Sweetenham
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Dean
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Sobecks
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Andresen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Kalaycio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Kalaycio.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Waterman, J., Rybicki, L., Bolwell, B. et al. Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. Bone Marrow Transplant 47, 488–493 (2012). https://doi.org/10.1038/bmt.2011.109

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.109

Keywords

This article is cited by

Search

Advanced search

Quick links